(s)-N-{(1S)-1-[2-(1-{[(3S,4R)-1-tertiary-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide | 455957-49-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (s)-N-{(1S)-1-[2-(1-{[(3S,4R)-1-tertiary-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide
• 英文别名: (s)-N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidine-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide；(s)-N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide；N-{(1S)-1-[2-(1-{[(3S,4R)-1-tertiary-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide；N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidine-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide；N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)-pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}pyrimidine-5-carboxamide；N-[(1S)-1-[2-[1-[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-carbonyl]piperidin-4-yl]-5-chlorophenyl]ethyl]pyrimidine-5-carboxamide
• CAS: 455957-49-0
• 化学式: C₃₃H₃₈ClF₂N₅O₂
• 分子量: 610.147
• InChiKey: ANELYYNVYLVLMR-NNZIQWQDSA-N

物化性质

• 沸点：
  745.2±60.0 °C(Predicted)
• 密度：
  1.259±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  43
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  78.4
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Combination therapy for the treatment of obesity
  申请人：MacNeil J. Douglas

  公开号：US20050288213A1

  公开（公告）日：2005-12-29

  The present invention relates to compositions comprising a NPY5 antagonist of formula I or II and an anti-obesity agent, useful for the treatment and prevention of diabetes, obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

  本发明涉及由式 I 或式 II 的 NPY5 拮抗剂和抗肥胖药组成的组合物。 和一种抗肥胖剂，可用于治疗和预防糖尿病、肥胖症和肥胖相关疾病。本发明进一步涉及通过施用本发明的组合物治疗或预防有需要的受试者的肥胖和肥胖相关疾病的方法。本发明进一步提供了用于实施这些方法的药物组合物、药剂和试剂盒。
• Combination Therapy for the Treatment of Obesity
  申请人：Amatruda M. John

  公开号：US20080064632A1

  公开（公告）日：2008-03-13

  The present invention relates to compositions comprising PYY, PYY 3-36 , or a PYY agonist, and an anti-obesity agent, useful for the treatment and prevention of obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.
• Compositions and Methods For the Treatment Of Obesity and Sexual Dysfunction
  申请人：MacCoss Malcolm

  公开号：US20080200376A1

  公开（公告）日：2008-08-21

  The present invention relates to methods of treating and preventing obesity and obesity-related disorders in a subject comprising administering a neurokinin-1 antagonist and an anti-obesity agent, such as a melanocortin 4 receptor agonist, to said subject. The present invention further related to methods of treating or preventing sexual dysfunction, including male erectile dysfunction, in a subject comprising administering a neurokinin-1 antagonist and a sexual dysfunction therapeutic agent, such as a melanocortin 4 receptor agonist, to said subject. The present invention further provides for pharmaceutical compositions and medicaments useful in carrying out these methods.